The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
TCT 2021 | IL-8 as a surrogate marker for pseudoprogression following anti-CD19 CAR-T in NHL
Predicting responses following CAR T-cell therapy is of major importance. In this interview, Arnon Nagler, MD, of Chaim Sheba Medical Center, Tel-Aviv, Israel, evaluates the use of serum interleukin-8 (IL8) as a surrogate marker of true immediate tumor progression following CAR-T therapy in patients with non-Hodgkin lymphoma (NHL). This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
